These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 25512404

  • 21. In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.
    Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416552
    [Abstract] [Full Text] [Related]

  • 22. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG, Voth D, Nichol K, Karlowsky JA, Noreddin AM, Hoban DJ.
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
    Lepak AJ, Zhao M, Liu Q, Wang P, Wang Y, Bader JC, Ambrose PG, Andes DR.
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
    [Abstract] [Full Text] [Related]

  • 24. In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
    [Abstract] [Full Text] [Related]

  • 25. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK, Tessier PR, Williams P, Nightingale CH, Nicolau DP.
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [Abstract] [Full Text] [Related]

  • 26. In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.
    Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036691
    [Abstract] [Full Text] [Related]

  • 27. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
    Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):845-51. PubMed ID: 11181370
    [Abstract] [Full Text] [Related]

  • 28. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR.
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [Abstract] [Full Text] [Related]

  • 29. In Vivo Pharmacodynamic Characterization of a Novel Odilorhabdin Antibiotic, NOSO-502, against Escherichia coli and Klebsiella pneumoniae in a Murine Thigh Infection Model.
    Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR.
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156
    [Abstract] [Full Text] [Related]

  • 30. In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model.
    Wicha WW, Craig WA, Andes D.
    J Antimicrob Chemother; 2019 Apr 01; 74(Suppl 3):iii5-iii10. PubMed ID: 30949706
    [Abstract] [Full Text] [Related]

  • 31. In vivo pharmacodynamic activity of daptomycin.
    Safdar N, Andes D, Craig WA.
    Antimicrob Agents Chemother; 2004 Jan 01; 48(1):63-8. PubMed ID: 14693519
    [Abstract] [Full Text] [Related]

  • 32. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Sugihara K, Sugihara C, Matsushita Y, Yamamura N, Uemori M, Tokumitsu A, Inoue H, Kakuta M, Namba E, Nasu H, Koga T.
    Antimicrob Agents Chemother; 2010 Dec 01; 54(12):5298-302. PubMed ID: 20921311
    [Abstract] [Full Text] [Related]

  • 33. Pharmacodynamics of imipenem in combination with β-lactamase inhibitor MK7655 in a murine thigh model.
    Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW.
    Antimicrob Agents Chemother; 2015 Feb 01; 59(2):790-5. PubMed ID: 25403667
    [Abstract] [Full Text] [Related]

  • 34. In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.
    Ferrari L, Iavarone L, Braggio S, Di Modugno E.
    Antimicrob Agents Chemother; 2003 Feb 01; 47(2):770-6. PubMed ID: 12543690
    [Abstract] [Full Text] [Related]

  • 35. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.
    Antimicrob Agents Chemother; 2016 Jan 01; 60(1):180-9. PubMed ID: 26482300
    [Abstract] [Full Text] [Related]

  • 36. In Vivo Pharmacodynamics of Cefquinome in a Neutropenic Mouse Thigh Model of Streptococcus suis Serotype 2 at Varied Initial Inoculum Sizes.
    Guo C, Liao X, Wang M, Wang F, Yan C, Xiao X, Sun J, Liu Y.
    Antimicrob Agents Chemother; 2016 Feb 01; 60(2):1114-20. PubMed ID: 26666923
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Bowker KE.
    Antimicrob Agents Chemother; 2013 Jun 01; 57(6):2451-6. PubMed ID: 23459495
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
    Keel RA, Crandon JL, Nicolau DP.
    Antimicrob Agents Chemother; 2011 Sep 01; 55(9):4028-32. PubMed ID: 21670184
    [Abstract] [Full Text] [Related]

  • 39. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM, Schmidt S, Zhuang L, Rand K, Derendorf H.
    Int J Antimicrob Agents; 2014 Jan 01; 43(1):60-7. PubMed ID: 24183800
    [Abstract] [Full Text] [Related]

  • 40. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.
    Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA.
    Antimicrob Agents Chemother; 2001 Jan 01; 45(1):13-22. PubMed ID: 11120938
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.